18 results
To evaluate the effects of COS with tamoxifen or letrozole compared to standard COS, on oocytes retrieved.
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
PrimaryTo investigate whether 5 years of extended adjuvant treatment with letrozole results in an improved DFS compared to 2.5 years treatment in patients with early breast cancer previously treated with endocrine agents for 5 yearsSecondaryTo…
Primary Objective: To evaluate the efficacy of intravenous NAC in comparison with placebo in terms of pain relief after unilateral inguinal hernia repair measured by a visual analogue scale (VAS 0-100) at day 1 after surgery.Secondary Objective(s):…
Primary objective: Determine whether treatment with a PI3K inhibitor (BYL719 or buparlisib) plus letrozole leads to an increase in pathologic response compared to treatment with placebo plus letrozole in patients with hormone receptor-positive HER2-…
The objective of this study is to investigate the effectivity on reducing or cessation of cocaine use of 1) working memory training, 2) N-acetylcysteine, 3) the combination of working memory training and N-acetylcysteine. Clinical measures (cocaine…
Primary: to estimate progression-free survival in patients treated with everolimus + letrozole in the first line setting.Secondary: overall response rate, clinical benefit rate, overall survival in the first line setting, progression free survival…
• To evaluate the effect of olaparib on exposure to anastrozole by determination of steady-state exposure to anastrozole in the presence and absence of steady-state exposure to olaparib• To evaluate the effect of anastrozole on exposure to olaparib…
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.
Primary Objective: Our primary objective is to investigate the effect of NAC on H2S levels in plasma in different patient groups, i.e. healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels…
to confirm that GMC 252 is absorbed in humansto determine in humans whether GMC 252 is cleaved, yielding diflunisal and N-acetylcysteine (NAC)to determine whether additional metabolites are formed with GMC-252 compared with diflunisal and NAC
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment. It is anticipated that the time on study (which is the time…
1. Determine the influence of acetylcysteine on thiopuirine related hepatotoxicity2. Determine the relation between hepatotoxicity, thiopurine metabolism, amino acid availablility and markers for oxidative stress3. Determine the effect of…
Primary: 1/ To evaluate the safety and tolerability of ribociclib with letrozole in men and postmenopausal women with HR+, HER2- aBC who received no prior hormonal therapy for advanced disease.Secondary: To assess the clinical efficacy of ribociclib…
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)
The primary objective of Study I3Y-MC-JPBM is to compare treatment with LY2835219 plus NSAI therapy versus placebo plus NSAI therapy with respect to PFS in postmenopausal women with HR+, HER2- locoregionally recurrent or metastatic breast cancer who…
Primary objective: Progression free survival (PFS) of treatment with letrozole plus LEE011 compared to treatment with letrozole plus placebo .Secondary objectives: Overall survival (OS), overall response rate (OR), overall clinical benefit rate,…
The primary objective of this study is to determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) compared to letrozole in combination with palbociclib in patients with ER +, HER2-advanced breast cancer…